Amphastar Pharmaceuticals, Inc. (AMPH)
AMPH Stock Price Chart
Explore Amphastar Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AMPH price movements and trends.
AMPH Company Profile
Discover essential business fundamentals and corporate details for Amphastar Pharmaceuticals, Inc. (AMPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jun 2014
Employees
2.03K
Website
https://www.amphastar.comCEO
Yongfeng Zhang
Description
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
AMPH Financial Timeline
Browse a chronological timeline of Amphastar Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $0.86, while revenue estimate is $186.89M.
Earnings released on 7 Aug 2025
EPS came in at $0.85 surpassing the estimated $0.71 by +19.72%, while revenue for the quarter reached $174.41M , missing expectations by -1.52%.
Earnings released on 7 May 2025
EPS came in at $0.74 surpassing the estimated $0.66 by +12.12%, while revenue for the quarter reached $170.53M , missing expectations by -1.46%.
Earnings released on 27 Feb 2025
EPS came in at $0.92 falling short of the estimated $1.01 by -8.91%, while revenue for the quarter reached $186.52M , missing expectations by -1.19%.
Earnings released on 6 Nov 2024
EPS came in at $0.96 falling short of the estimated $0.99 by -3.03%, while revenue for the quarter reached $188.82M , missing expectations by -1.70%.
Earnings released on 7 Aug 2024
EPS came in at $0.94 surpassing the estimated $0.77 by +22.08%, while revenue for the quarter reached $182.39M , beating expectations by +6.70%.
Earnings released on 8 May 2024
EPS came in at $1.04 surpassing the estimated $0.96 by +8.33%, while revenue for the quarter reached $171.84M , missing expectations by -1.65%.
Earnings released on 28 Feb 2024
EPS came in at $0.88 falling short of the estimated $0.93 by -5.38%, while revenue for the quarter reached $178.11M , beating expectations by +1.39%.
Earnings released on 8 Nov 2023
EPS came in at $1.15 surpassing the estimated $0.69 by +66.67%, while revenue for the quarter reached $180.56M , beating expectations by +2.22%.
Earnings released on 8 Aug 2023
EPS came in at $0.65 surpassing the estimated $0.56 by +16.07%, while revenue for the quarter reached $145.71M , beating expectations by +6.07%.
Earnings released on 9 May 2023
EPS came in at $0.62 surpassing the estimated $0.48 by +29.17%, while revenue for the quarter reached $140.02M , beating expectations by +2.71%.
Earnings released on 28 Feb 2023
EPS came in at $0.73 surpassing the estimated $0.41 by +78.05%, while revenue for the quarter reached $135.02M , beating expectations by +6.16%.
Earnings released on 7 Nov 2022
EPS came in at $0.38 falling short of the estimated $0.39 by -2.56%, while revenue for the quarter reached $120.13M , missing expectations by -4.64%.
Earnings released on 8 Aug 2022
EPS came in at $0.39 surpassing the estimated $0.35 by +11.43%, while revenue for the quarter reached $123.47M , beating expectations by +4.56%.
Earnings released on 9 May 2022
EPS came in at $0.47 surpassing the estimated $0.36 by +30.56%, while revenue for the quarter reached $120.37M , beating expectations by +6.21%.
Earnings released on 10 Mar 2022
EPS came in at $0.42 surpassing the estimated $0.36 by +16.67%, while revenue for the quarter reached $120.89M , beating expectations by +8.30%.
Earnings released on 8 Nov 2021
EPS came in at $0.46 surpassing the estimated $0.24 by +91.67%, while revenue for the quarter reached $112.20M , beating expectations by +43.66%.
Earnings released on 9 Aug 2021
EPS came in at $0.21 matching the estimated $0.21, while revenue for the quarter reached $101.66M , beating expectations by +0.28%.
Earnings released on 6 May 2021
EPS came in at $0.27 surpassing the estimated $0.19 by +42.11%, while revenue for the quarter reached $103.02M , beating expectations by +21.21%.
Earnings released on 15 Mar 2021
EPS came in at $0.16 surpassing the estimated $0.14 by +14.29%, while revenue for the quarter reached $95.92M .
Earnings released on 6 Nov 2020
EPS came in at $0.15 surpassing the estimated $0.13 by +15.38%, while revenue for the quarter reached $83.43M .
AMPH Stock Performance
Access detailed AMPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.